Pfizer Inc. released its full-year 2025 financial guidance, projecting revenues between $61.0 billion and $64.0 billion, exceeding consensus estimates of $63.28 billion. The company expects revenue from COVID-19 products to remain consistent with 2024, excluding one-time Paxlovid revenue.
Pfizer faces an estimated $1 billion net unfavorable revenue impact due to changes under the Inflation Reduction Act (IRA), particularly Medicare Part D redesign. However, benefits like the $2,000 annual out-of-pocket cap are expected to outweigh these offsets through eliminating the Coverage Gap Discount Program and adding manufacturer discounts in certain coverage phases.
Operational revenue growth is projected at flat to 5% year-over-year from the midpoint of 2024 baseline guidance, excluding non-recurring items. Adjusted Selling, Informational, and Administrative expenses are expected between $13.3 billion and $14.3 billion.
The company projects adjusted earnings per share (EPS) of $2.80 to $3.00 in 2025, driven by higher revenues and improved operating margins from ongoing cost management. Pfizer reaffirmed its 2024 full-year guidance and expects to continue improving its operating margins with focused financial discipline.
Source: https://www.benzinga.com/general/biotech/24/12/42530634/pfizer-does-not-anticipate-material-changes-to-us-vaccine-policy-from-the-incoming-administration-in-2025